The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of combination of temozolomide and pazopanib in patients with advanced pancreatic neuroendocrine tumors (PNET).
 
Halla Sayed Nimeiri
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
 
Sachin Gopalkrishn Pai
No Relationships to Disclose
 
E. Gabriela Chiorean
Consulting or Advisory Role - Celgene; Genentech; Merrimack; Pfizer
Research Funding - Bristol-Myers Squibb; Celgene; Genentech; Incyte; PRISM Pharma; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Celgene; Celgene
 
Alfred Rademaker
Research Funding - Siemens (Inst)
Other Relationship - JAMA-Journal of the American Medical Association
 
Sheetal Mehta Kircher
No Relationships to Disclose
 
Mary Frances Mulcahy
No Relationships to Disclose
 
Steven J. Cohen
Consulting or Advisory Role - Bayer; Genentech; Taiho Pharmaceutical
 
Crystal Shereen Denlinger
Consulting or Advisory Role - Lilly; Merrimack
Research Funding - Astex Pharmaceuticals (Inst); Bayer (Inst); Genentech/Roche (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Merrimack (Inst); OncoMed (Inst); Pfizer (Inst)
 
Vaibhav Sahai
No Relationships to Disclose
 
Mark Zalupski
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Boston Biomedical; Celgene; EMD Serono; Genentech/Roche; Ipsen; Janssen Oncology; Lilly/ImClone; Novartis; Pharmacyclics; Symphony Evolution; Targovax; Threshold Pharmaceuticals; Vertex
Research Funding - Abbvie (Inst); Bayer (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Loxo (Inst); Merrimack (Inst); Novartis (Inst); OncoMed (Inst); Symphony Evolution (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Abbvie; Boston Biomedical; Celgene; Genentech/Roche; Janssen Oncology
Other Relationship - Momenta Pharmaceuticals; Symphony Evolution
 
Al Bowen Benson
Consulting or Advisory Role - Alchemia; Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; Genomic Health; Infinity Pharmaceuticals; Lilly/ImClone; Merck Serono; Merck/Schering Plough; National Cancer Institute; Pharmacyclics; Precision Therapeutics; Sanofi; Spectrum Pharmaceuticals; Taiho Pharmaceutical; Vicus Therapeutics
Research Funding - advanced accelerator applications; Alchemia; Amgen; Astellas Pharma; AVEO; Bayer/Onyx; EMD Serono (Inst); Genentech (I); Gilead Sciences; Infinity Pharmaceuticals; Merck Serono (Inst); Novartis
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals